Skip to main content
Roy Freeman, MD, Neurology, Boston, MA

Roy L Freeman MD

Neurophysiology


Professor, Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School

Join to View Full Profile
  • 1 Deaconess RdBeth Israel Deaconess Med Ctr Palmer 111Boston, MA 02215

  • Phone+1 617-632-8454

Dr. Freeman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Beth Israel Deaconess Medical Center/Harvard Medical School
    Beth Israel Deaconess Medical Center/Harvard Medical SchoolResidency, Neurology, 1979 - 1982
  • Mass General Brigham/Brigham and Women's Hospital
    Mass General Brigham/Brigham and Women's HospitalInternship, Internal Medicine, 1978 - 1979
  • University of Cape Town Faculty of Medicine
    University of Cape Town Faculty of MedicineClass of 1974

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1980 - 2025
  • Neurology
    American Board of Psychiatry and Neurology Neurology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • State-of-the-Art Review  
    Roy Freeman, Mitchell G Miglis, Christopher Gibbons, Pearl Jones, ScienceDirect

Lectures

  • Diabetic Peripheral Neuropathy: More Effective Treatments Needed 
    43rd Annual Meeting, Amsterdam, The Netherlands
  • Diabetic Peripheral Neuropathy: More Effective Treatments Needed 
    European Association for the Study of Diabetes, 43rd Annual Meeting, Amsterdam, The Netherlands

Press Mentions

  • CND Life Sciences Announces Publication of Study Demonstrating Clinical Utility of the Syn-One Test® as an Important Aid in the Diagnosis and Treatment of Neurodegenerative Diseases
    CND Life Sciences Announces Publication of Study Demonstrating Clinical Utility of the Syn-One Test® as an Important Aid in the Diagnosis and Treatment of Neurodegenerative DiseasesDecember 18th, 2024
  • CND Life Sciences Announces Publication of Study Demonstrating Clinical Utility of the Syn-One Test® as an Important Aid in the Diagnosis and Treatment of Neurodegenerative Diseases
    CND Life Sciences Announces Publication of Study Demonstrating Clinical Utility of the Syn-One Test® as an Important Aid in the Diagnosis and Treatment of Neurodegenerative DiseasesDecember 18th, 2024
  • CND Life Sciences Enters into Licensing and Collaboration Agreement to Advance Diagnostic Technology for Neurodegenerative Diseases
    CND Life Sciences Enters into Licensing and Collaboration Agreement to Advance Diagnostic Technology for Neurodegenerative DiseasesMarch 22nd, 2023
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: